44 results about "Anti hyperglycemic" patented technology

A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.

A pharmaceutical agent having GPR40 receptor agonistic action, particularly a compound which is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus. The present inventors have examined a compound having GPR40 receptor agonistic action, confirmed that an oxadiazolidinedione compound which has a substituent such as a benzyl group, etc. linked with a substituent such as a phenyl group, etc. through a linker at the 2-position of an oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof has an excellent GPR40 agonistic activity, and thus completed the invention. The oxadiazolidinedione compound has excellent insulin secretagogue action and anti-hyperglycemic action, and therefore can be used as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.

Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, R¹, R², R³, R⁴, R⁵, X, Alk¹, Alk², Ar¹, and Ar² are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR/PPARalpha, RXR/PPARgamma, and RXR/PPARdelta heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists.

This invention provides a-glucosidase inhibitors isolated from Oroxylum indicum an Indian medicinal plant. Particularly, this invention provides hexane and acetone fraction of Oroxylum indicum wherein the hexane fraction comprises a-glucosidase active compounds of oroxylin A, chrysin and baicalain and acetone fraction comprises the compounds of oroxylin A, chrysin, baicalain, methoxy chrysin and oroxyloside methyl ester. This invention also relates to a process for the isolation of a-glucosidase inhibitory active compounds from the above said hexane and acetone fraction of Oroxylum indicum. This invention also provides the use of potent intestinal a-glucosidase inhibitors as active ingredients that can be used in pharmaceuticals, food products, health foods and specialized health care foods as anti hyperglycemic agent for prevention and treatment of post prandial hyperglycemia, hyperglycemia and related conditions in diabetes mellitus, obesity and disease conditions requiring hyperglycemic control as well as inhibition of a-glucosidase activity.

The invention provides a diabetes full-nutrition formula food and a preparation method thereof. The formula food comprises maltodextrin, resistant dextrin, xylitol, fruit and vegetable powder, gingerpowder, soy isolate protein, whey protein, vegetable fat powder, inulin, fructo-oligosaccharide, konjaku flour, probiotic powder, retinyl acetate, vitamin D3 powder, D-alpha-tocopheryl acetate powder,vitamin K1, thiamine hydrochloride, riboflavin, pyridoxine hydrochloride, cyanocobalamin, nicotinamide, folic acid, D-calcium pantothenate, L-sodium ascorbate, D-biotin, copper sulfate, magnesium sulfate, ferrous sulfate, zinc citrate, manganese sulfate, calcium hydrophosphate, potassium iodide, sodium selenite and potassium chloride. The diabetes full-nutrition formula food is rich in nutrition,can improve the microenvironment in the body of a patient, can resist oxidative stress of hyperglycemia on the body, and reduces body injury. The preparation method of the formula food has the advantages that the process is simple and easy to control and the formula food is suitable for wide popularization.

Selected diabetic patients reveal significant glycemic control after bariatric surgical or endoscopic duodenal bypass. This controlling effect appears to occur partly because of an enhanced Glucagon-Like Peptide 1 (GLP1) release from intestinal L-cells. These procedures may also cause complications such as nutritional deficiencies. The present invention provides a stent. The method that places this stent in the ileum to activate the endogenous GLP1 release is a safer alternative to control the diabetes mellitus. However, the less mobile wall of the ileum next to the proximal stent rim can trigger an unwanted telescoping of the intestine, which is known as intussusception. An embodiment of this invention illustrates the characteristics of a stent that can prevent a likely intussusception and consequently be more confidently applied in the ileum to maintain or restore the ileal patency in general or for its anti-hyperglycemic effect in particular.

The invention discloses a traditional Chinese medicine prescription anti-hyperglycemic calculi-dissolving oral liquid and process for preparation. Firstly, walnut kernel, sesame seed, pinenut, and hemp seed are extracted, and the grease is further stored for standby, secondly, nucleolus is extracted, the grease is stored for standby, the oil cake is dipped with grain alcohol, and is filtered, and the grain alcohol is recovered from the filter liquid and the filter liquid is condensed, thirdly, the extract oils of the walnut kernel, the sesame seed, the pinenut, and the hemp seed, the nucleolusl oil, the extract liquid of the nucleolusl oil cake, and bee honey are mixed, churned, and are hermitically encapsulated and disinfected. The invention can evidently improve bile salt density in a liner, and can evidently improve the effect of lecithine density in a liner, and has the effects of evidently reducing blood fat, dissolving and discharging calculi, curing coronary disease, and reducing pressure, and is beneficial to gallbladder.

The invention relates to the technical field of protein extraction. In order to solve the problem that a large amount of by-products are generated during processing of Nibea japonica and the resourceutilization rate is low, the invention provides a preparation method of dipeptidyl peptidase-IV inhibitory peptide derived from collagen of swim bladder of Nibea japonica. The method comprises the following steps: (1) pretreating swim bladder of Nibea japonica, then extracting collagen with 5 wt% acetic acid combined with pepsin, and carrying out centrifugal drying to obtain collagen of swim bladder of Nibea japonica; (2) carrying out enzymolysis on the collagen of swim bladder of Nibea japonica by the use of compound enzyme so as to obtain collagen peptide of swim bladder of Nibea japonica; and (3) screening a kit by combining the collagen peptide of swim bladder of Nibea japonica with dipeptidyl peptidase so as to obtain the dipeptidyl peptidase-IV inhibitory peptide. With the swim bladder of Nibea japonica as the main raw material and through an efficient technology, the dipeptidyl peptidase-IV inhibitory peptide is prepared. The inhibitory peptide has a good effect of inhibiting dipeptidyl peptidase-4, and has a good anti-hyperglycemic effect.

Disclosed is a sphingomyelin-containing material which can be produced in a large quantity at low cost. Also disclosed is an useful use application of a sphingomyelin-containing material. Specifically disclosed is an anti-hyperglycemic and/or anti-hyperlipidemic agent comprising a material containing a sphingomyelin derived from an avain skin as an active ingredient.

The invention relates to the field of beverages, in particular to an anti-sangao tea. Choose 5-10 parts of ginkgo leaf powder, 20-40 parts of tartary buckwheat, 5-10 parts of motherwort, and 5-10 parts of wild chrysanthemum. The invention is made of various natural substances, has no toxic and side effects, and the synergistic effect of various substances can effectively prevent and reduce the symptoms of three highs.

The present invention relates to pentose and pentose derivatives that are effective at increasing glucose transport in a non-insulin dependent manner, and to uses thereof for a) treating and/or preventing hyperglycemia; b) treating and/or preventing the complications of hyperglycemia; c) treating diabetes; d) increasing the rate of cellular glucose transport; e) increasing the rate of cellular glucose uptake; f) improving the ability of a subject to metabolize glucose; g) treating daily blood glucose fluctuations; h) reducing blood sugar levels; i) reducing the dosage of anti-diabetic medication needed for treatment of diabetes. The present invention further provides novel pentose derivatives having beneficial properties in terms of pharmacokinetics, to pharmaceutical compositions comprising these novel compounds and uses thereof.

The invention provides new use of lignin. The experiment shows that the IC50 value of lignin of which the relative molecular weight is 12,000Da is 0.076mu M, and the activity of alpha-glucosaccharase can be effectively restrained. Therefore, the polymer can be used as an anti-hyperglycaemic function factor, so as to prevent and treat postprandial hyperglycemia, hyperglycemia and related diseases in diabetes mellitus, obesity and the diseases of requiring to control hyperglycemia and restrain the activity of alpha-glucosaccharase.